Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Key Highlights
- ➤AUCATZYL revenue $41.2 million, up 95% year-over-year
- ➤2026 AUCATZYL revenue expected at or above $150 million
- ➤Gross margin rose to 57% from negative margin year-over-year
- ➤Net loss narrowed to $55.1 million from $79.1 million
- ➤Cash, equivalents and securities totaled $248.4 million at September 30
Expert Statements
Christian Itin, Chief Executive Officer of Autolus Therapeutics
“We delivered another strong quarter of AUCATZYL revenue, primarily driven by growth within existing authorized treatment centers as physicians gain positive experience with the therapy, and supported by real-world data reported through the ROCCA consortium. Importantly, we also continue to improve the gross margin, with strong execution on manufacturing efficiency initiatives.”
Christian Itin, Chief Executive Officer of Autolus Therapeutics
“AUCATZYL’s performance in adult r/r B-ALL is a key near-term value driver. Longer term, we believe expanding obe-cel across all stages of ALL and into autoimmune indications offers meaningful opportunities for scalable growth, leveraging its favorable profile and Autolus’ proven manufacturing and commercial capabilities. We look forward to autoimmune program data presentations at upcoming key medical meetings.”
* Company reports AUCATZYL(®) (obecabtagene autoleucel; obe-cel) net product revenue of $41.2 million, an increase of 95% year-over-year; now expects full-year 2026 AUCATZYL net product revenue to be at or exceeding upper end of $150 million from prior guidance * Gross margin increased to 57%, driven by growing volumes and manufacturing efficiency initiatives * Obe-cel clinical development programs progressing with trial enrollment ongoing in lupus nephritis, pediatric ALL and progressive multiple sclerosis (MS) * Conference call to be held today at 8:30am EST/1:30pm GMT: conference call participants should pre-register using the link at the bottom of this press release LONDON and GAITHERSBURG, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announces its operational and financial results for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.